I think you're in the wrong thread or you are confused.
Mesoblast is a biopharma in about to get a first product through a P3 trial, not sure how you could read into it a claim to be "investment grade". Take a look at the larger investors, DYOR, look at what these businesses investment targets are.
And then there are the other P3 and P2 trials which you can DYOR on.
And where does this come from? Or is it just your favourite piece of text?
"and its history is chequered to say the least."
Ann: MSB Enters Into $75 Million Non-Dilutive Credit Facility, page-149
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.003(0.23%) |
Mkt cap ! $1.230B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $3.160M | 2.917M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 60118 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 21880 | 12 |
View Market Depth
| Last trade - 13.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |